Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
about
The spread, treatment, and prevention of HIV-1: evolution of a global pandemicThe qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremiaIncreased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usageImmunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/mlContribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infectionT helper cell activation and human retroviral pathogenesisCatalytic antibodies to HIV: physiological role and potential clinical utilityHLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressorsReplicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutationNatural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversificationThe Antibody Response against HIV-1Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapyTwin studies demonstrate a host cell genetic effect on productive human immunodeficiency virus infection of human monocytes and macrophages in vitroNew concepts in HIV-1 vaccine developmentAdenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophagesHuman IgM monoclonal antibody to ganglioside GM2 and complement suppress virus propagation in ex vivo cultures of lymphocytes from HIV-1 infected patientsImmunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trialAltering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccineHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1Conservation of the central proline-rich (PxxP) motifs of human immunodeficiency virus type 1 Nef protein during the disease progression in two hemophiliac patients.HIV-1 Disease Progression and Survival in an Adult Population in Zimbabwe: Is There an Effect of the Mannose Binding Lectin Deficiency?The Viral Model for AIDS: Paradigmatic Dominance, Politics, or Best Approximation of Reality?CD8(+)T-cell-mediated control of HIV-1 and SIV infection.HIV-1 Vaccine Trials: Evolving Concepts and DesignsNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140An endogenous HIV envelope-derived peptide without the terminal NH3+ group anchor is physiologically presented by major histocompatibility complex class I molecules."Negative vaccination" by specific CD4 T cell tolerisation enhances virus-specific protective antibody responsesInduction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptideFive HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity.Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous Simian Immunodeficiency Virus-specific CD8(+) T cell clones during acute and chronic infection of rhesus macaquesA dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.A bereavement support group intervention is longitudinally associated with salutary effects on the CD4 cell count and number of physician visitsPlasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.Meta-analysis to test the association of HIV-1 nef amino acid differences and deletions with disease progressionImmunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil.
P2860
Q22241890-44140163-9089-40F7-9D3F-3C51714E195DQ22248074-AECE977A-56CB-4652-9DC4-ABDEBE1F76FDQ24531468-E88E4EA6-590F-4052-83BC-F96AE5E5EDBCQ24531479-2A88B083-B2EB-4B2B-8BD0-AED6DF8282D4Q24545015-CE60F476-62F2-42E0-B1A4-72F874E3FCD3Q24550678-442DD6CB-6C13-46F7-9A16-3BDCC2022ED1Q24650854-67C1B163-BD6F-423C-A393-6048EB081B1DQ24655912-BECA4667-E157-454F-B0C3-52CC2262064EQ24676982-276403F7-892F-4546-B85B-6D39BCBEE849Q24798257-A9C362A0-4D8F-4429-A61D-64E8E158F60BQ24817186-1791C531-740A-4170-9118-2993CA5F57E2Q27000889-5C4B9EB8-A6C8-445F-917C-88AE6C474FA8Q27313556-BF41C0BD-216C-42D3-AE1E-B1943A862E10Q27480750-7D056F92-5BB1-46BF-B870-8F3DF1BAB66CQ28067027-77C4EDEB-82C4-4322-A86B-6426A7E89930Q28248983-10601D76-B52A-471C-9635-B9F7ADC47213Q28374635-A6A96444-0BB9-4D86-A195-6ABF9537DD70Q28469122-BBE972EB-5B39-4BBA-B514-376A801B936EQ28482252-A3B6E1FB-05D2-4600-90E5-2BCE24BDB5DEQ29307502-66034ABE-A7DF-45E5-B42D-C15E1F03B84FQ29619512-E1336D17-73F2-4FBE-86BE-21FB69AA619FQ30175327-381DF69B-E987-4D0B-A1AF-C2482FB1354FQ30378916-5088149D-DB29-4C6E-A5EC-A2ACDE1D89FCQ30393620-DDB4FBF8-4F17-48FA-9E0D-3D1C7CD4FA60Q30397667-5D37E085-FE00-4BCF-BD62-2B758E061B8BQ30425520-49FB256E-6C52-4FA4-A2F5-751020705E4CQ30431941-EDC5FB5A-42AF-46BA-8A64-1AB165771B60Q31019004-B2829152-6641-4882-AABE-18CA93B8DDBAQ33305432-52C5AF7A-4B9A-4533-A6A0-3A208C88B76AQ33307523-9401F153-855F-4280-A81C-FCF81EDC37C3Q33530024-0D1C5162-B173-42B0-B05D-E1716F503784Q33554963-E5E3AA73-0643-4EDF-B438-EE9EC654F770Q33604871-ADD32E41-6ECC-4A7D-B9C2-FD1AB7E3B8A3Q33611645-444622DF-C44D-4D31-89AE-9E3967E04A23Q33655217-65BF4A10-2257-434C-AD1C-781A3434EF94Q33690988-395A1B1B-1776-4E01-B505-B457F203E505Q33715758-7D9D9A44-49F7-4468-8477-36C518A155EBQ33721788-8BF911BD-F414-4300-B9A0-EACF791FB9A3Q33725746-DF0E4538-F659-458D-8D86-341EFD5DE691Q33755753-047F609F-9B86-4AAA-B3DF-CE061ABD4CB4
P2860
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Virologic and immunologic char ...... iciency virus type 1 infection
@ast
Virologic and immunologic char ...... iciency virus type 1 infection
@en
Virologic and immunologic char ...... iciency virus type 1 infection
@nl
type
label
Virologic and immunologic char ...... iciency virus type 1 infection
@ast
Virologic and immunologic char ...... iciency virus type 1 infection
@en
Virologic and immunologic char ...... iciency virus type 1 infection
@nl
prefLabel
Virologic and immunologic char ...... iciency virus type 1 infection
@ast
Virologic and immunologic char ...... iciency virus type 1 infection
@en
Virologic and immunologic char ...... iciency virus type 1 infection
@nl
P2093
P1476
Virologic and immunologic char ...... iciency virus type 1 infection
@en
P2093
P356
10.1056/NEJM199501263320401
P407
P577
1995-01-26T00:00:00Z